Class 2 Medicines Recall: Lipitor (Atorvastatin) 80mg film-coated tablets / Atorvastatin 80mg film-coated tablets, Almus livery

Pfizer is recalling the above batches as a precaution due to an out of specification result for microbiological testing during routine stability studies on a batch of the product which was not released to the market. (EL (17) A/12)

Product information

MDR number

MDR 96-11/17

Company name

Pfizer Ireland Pharmaceuticals

Product description

Lipitor (Atorvastatin) 80mg film-coated tablets (PL 39933/0004) Atorvastatin 80mg film-coated tablets, Almus livery (PL 39933/0012)

Batch number/expiry

Batch Number Expiry Date Pack Size First Distributed
T43157 (Almus) 31 Jan 2020 1 x 28 10 Sep 2017
T43166 (Lipitor) 31 Jan 2020 1 x 28 05 Sep 2017
T43170 (Lipitor) 31 Jan 2020 1 x 28 30 Aug 2017

Brief description of the problem

Pfizer is recalling the above batches as a precaution due to an out of specification result for microbiological testing during routine stability studies on a batch of the product which was not released to the market. The above batches were identified as being potentially affected by the same issue during the root cause investigation, although no out of specification microbiological results have been reported for these batches.

Advice for healthcare professionals & wholesalers

Remaining stock of these batches should be quarantined and returned to the original supplier for credit.

Medical information enquiries

For Medical information enquiries, please contact Pfizer Medical Information on 01304 616161

Stock enquiries

For stock enquiries, please contact your local branch of Alliance Healthcare

Download document

Class 2 Medicines Recall: Lipitor (Atorvastatin) 80mg film-coated tablets / Atorvastatin 80mg film-coated tablets, Almus livery

Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter. NHS regional teams are asked to forward this to relevant clinics, community pharmacists and dispensing GPs for action; and to General Practitioners for information.

Updates to this page

Published 27 November 2017